OCX-063 is under clinical development by OccuRx and currently in Phase I for Proliferative Vitreoretinopathy (PVR). According to GlobalData, Phase I drugs for Proliferative Vitreoretinopathy (PVR) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OCX-063 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OCX-063 is under development for the treatment of non-proliferative diabetic retinopathy, proliferative vitreoretinopathy, wet (neovascular / exudative) macular degeneration, chronic kidney disease and focal segmental glomerulosclerosis (FSGS). It is administered through oral route and formulated in the form of capsule. It was under development for diabetic nephropathy.
For a complete picture of OCX-063’s drug-specific PTSR and LoA scores, buy the report here.